Tests ABP-671 in adults with chronic kidney disease and high uric acid
Tests ABP-671, alone or with febuxostat, in adults with kidney disease and high uric acid.
Plain-language title generated from the registry record
Registry title: Evaluate the Efficacy and Safety of ABP-671 in Subjects With Chronic Kidney Disease and Hyperuricaemia
Key facts
- Where
- Beijing, Hangzhou, Nanjing, and Shanghai, ChinaSee the 7 sites
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT07323095, who can take part
Where in China
- Beijing Tsinghua Changgung HospitalBeijing, ChinaNot yet recruiting
- Peking University First HospitalBeijing, ChinaNot yet recruiting
- Xuanwu Hospital, Capital Medical UniversityBeijing, ChinaNot yet recruiting
- Sir Run Run Shaw Hospital , affiliated with the Zhejiang University School of MedicineHangzhou, ChinaNot yet recruiting
- Zhejiang Provincial People's HospitalHangzhou, ChinaNot yet recruiting
- Jiangsu Province HospitalNanjing, ChinaNot yet recruiting
- Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of MedicineShanghai, ChinaNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Atom Therapeutics Co., Ltd
- Trial code
- NCT07323095
- Record updated
- 2 November 2026
- Original description
This is a phase 2, international, multicenter, randomized, double blind, placebo-controlled trial to evaluate the efficacy and safety of ABP-671 in subjects with CKD and hyperuricaemia, to preliminarily evaluate the efficacy of ABP-671 in the treatment of subjects with CKD and hyperuricemia, primary Efficacy Endpoint is change in UACR from baseline to Week 40Read full original descriptionShow less
A Phase 2, International, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of ABP-671 in Subjects With Chronic Kidney Disease and Hyperuricaemia
This is a phase 2, international, multicenter, randomized, double blind, placebo-controlled trial to evaluate the efficacy and safety of ABP-671 in subjects with CKD and hyperuricaemia, to preliminarily evaluate the efficacy of ABP-671 in the treatment of subjects with CKD and hyperuricemia, primary Efficacy Endpoint is change in UACR from baseline to Week 40
Inclusion: Male or female aged 18-75 years , who voluntarily participate in this clinical trial, understand and comply with the procedures stipulated in this study; Patients who have been diagnosed with CKD based on Clinical Practice Guideline; During screening, body mass index (BMI) was ≥18.0 and ≤ 40.0 kg/m2; The sUA levels > 420 μmol/L (7.0 mg/dL).
Exclusion: Subjects who have participated in another clinical study during the screening period are within 30 days of the last dose of the study drug in another study; History of renal transplantation; Subjects with mental disorders who are unable to communicate normally with the investigator; Liver function abnormality: aspartate aminotransferase or alanine aminotransferase, or alkaline phosphatase > 3 times the upper limit of normal value (ULN); The 24-hour urinary protein ≥ 3.5 g/day; The investigator judged that the subject was not suitable for participation in this study.